Want to see TSE:NARA full AI Analyst Report?
NARA Stock Chart & Stats
C$0.51
C$0.04(33.33%)
At close: 4:00 PM EST
C$0.51
C$0.04(33.33%)
Day’s Range― - ―
52-Week RangeC$0.29 - C$2.57
Previous CloseN/A
Volume0.00
Average Volume (3M)110.39K
Market Cap
C$5.20M
Enterprise ValueC$4.94M
Total Cash (Recent Filing)C$40.85K
Total Debt (Recent Filing)C$482.87K
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding14,046,870
10 Day Avg. Volume77,322
30 Day Avg. Volume110,395
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-3.87
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Software Industry ExposureBeing in the Software - Application sector signals a structurally scalable business model and potential for recurring revenue and operating leverage if product-market fit is achieved. Over 2–6 months this industry positioning supports long-term margin upside versus commodity sectors.
Modest Absolute DebtBalance-sheet text notes debt around $483k in the TTM, a modest nominal level. Lower absolute debt reduces fixed interest obligations and short-term refinancing pressure, preserving flexibility while the company pursues strategic pivots or fundraising over the medium term.
Lower Equity VolatilityA beta ~0.68 indicates the stock has historically moved less than the market, which can reflect lower market-driven volatility. For capital-raising and partnership discussions, reduced price volatility can be a durable advantage versus more chaotic small-cap peers.
Bears Say
No RevenueThe company reports no revenue across annual periods and TTM, eliminating organic operational cash generation. Without identifiable top-line inflows, the business cannot offset fixed costs or demonstrate product-market traction, making growth and margin sustainability uncertain.
Negative Shareholders' EquityConsistently negative shareholders' equity reflects accumulated losses and materially weakens solvency. Negative equity limits financial flexibility, increases dilution risk when raising capital, and reduces creditor confidence—persistent constraints on strategic options.
Sustained Cash BurnTTM operating cash flow of roughly -$2.1M and an accelerating cash burn profile indicate ongoing funding needs. Persistently negative operating and free cash flow imply reliance on external financing; absent a clear path to self-funding, long-term viability is contingent on capital access.
PanGenomic Health, Inc. Class A News
NARA FAQ
What was PanGenomic Health, Inc. Class A’s price range in the past 12 months?
PanGenomic Health, Inc. Class A lowest stock price was C$0.29 and its highest was C$2.57 in the past 12 months.
What is PanGenomic Health, Inc. Class A’s market cap?
PanGenomic Health, Inc. Class A’s market cap is C$5.20M.
When is PanGenomic Health, Inc. Class A’s upcoming earnings report date?
PanGenomic Health, Inc. Class A’s upcoming earnings report date is Aug 27, 2026 which is in 53 days.
How were PanGenomic Health, Inc. Class A’s earnings last quarter?
Currently, no data Available
Is PanGenomic Health, Inc. Class A overvalued?
According to Wall Street analysts PanGenomic Health, Inc. Class A’s price is currently Overvalued.
Does PanGenomic Health, Inc. Class A pay dividends?
PanGenomic Health, Inc. Class A does not currently pay dividends.
What is PanGenomic Health, Inc. Class A’s EPS estimate?
PanGenomic Health, Inc. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PanGenomic Health, Inc. Class A have?
PanGenomic Health, Inc. Class A has 14,046,870 shares outstanding.
What happened to PanGenomic Health, Inc. Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PanGenomic Health, Inc. Class A?
Currently, no hedge funds are holding shares in TSE:NARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PanGenomic Health, Inc. Class A
Pangenomic Health Inc. operates as a precision health company in Canada. The company offers Nara App, a telehealth mental health app that provides users with personalized information about non-pharmaceutical alternatives to address mental health concerns; and Mindleap, a telehealth platform, which provides various tools and resources to help individuals understand and improve their inner wellness. It also provides MUJN, a clinical decision support platform that offers health practitioners with access to the consumer's mobile app data and their diagnostic reports. The company was formerly known as Zetta Capital Corp. and changed its name to Pangenomic Health Inc. in December 2021. The company was incorporated in 2015 and is based in Vancouver, Canada.
Technical Analysis
Diagnos
―
nDatalyze Corp
―
Rocket Doctor AI
―
UniDoc Health Corp
―
DiagnaMed Holdings Corp.
―
Options Prices
Currently, No data available
---